Literature DB >> 10958589

Development of multidrug-resistance convertors: sense or nonsense?

L van Zuylen1, K Nooter, A Sparreboom, J Verweij.   

Abstract

This review describes the clinical relevance of the two drug transporters P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) and the in vitro phenomenon which is referred to as multidrug resistance (MDR). The attempts to try to block these resistance mechanisms are summarized with specific attention for the intentionally designed "second generation" MDR-convertors. Potential explanations of the limited clinical success rate are given and recommendations for the design of future studies provided.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10958589     DOI： 10.1023/a:1006487003814

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  144 in total

1.  The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.

Authors:  C L Willman
Journal:  Semin Hematol       Date:  1997-10       Impact factor: 3.851

2.  Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

Authors:  U Vanhoefer; S Cao; A Harstrick; S Seeber; Y M Rustum
Journal:  Ann Oncol       Date:  1997-12       Impact factor: 32.976

3.  Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.

Authors:  M Fillpits; R W Suchomel; G Dekan; W Stiglbauer; K Haider; D Depisch; R Pirker
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.

Authors:  M Webb; M Brun; M McNiven; D Le Couteur; P Craft
Journal:  Br J Haematol       Date:  1998-08       Impact factor: 6.998

5.  Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.

Authors:  S Naito; K Koike; M Ono; T Machida; S Tasaka; A Kiue; H Koga; J Kumazawa
Journal:  Oncol Res       Date:  1998       Impact factor: 5.574

6.  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Authors:  E Fuse; H Tanii; N Kurata; H Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; D Headlee; W D Figg; S G Arbuck; A M Senderowicz; E A Sausville; S Akinaga; T Kuwabara; S Kobayashi
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

7.  Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

Authors:  R Advani; H I Saba; M S Tallman; J M Rowe; P H Wiernik; J Ramek; K Dugan; B Lum; J Villena; E Davis; E Paietta; M Litchman; B I Sikic; P L Greenberg
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

8.  Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

Authors:  L Beketic-Oreskovic; G E Durán; K G Chen; C Dumontet; B I Sikic
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

9.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Authors:  J Verweij; H Herweijer; R Oosterom; M E van der Burg; A S Planting; C Seynaeve; G Stoter; K Nooter
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

10.  Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.

Authors:  E Ota; Y Abe; Y Oshika; Y Ozeki; M Iwasaki; H Inoue; H Yamazaki; Y Ueyama; K Takagi; T Ogata
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640
View more
  15 in total

1.  siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.

Authors:  Meysam Abbasi; Hamidreza Montazeri Aliabadi; Elaine H Moase; Afsaneh Lavasanifar; Kamaljit Kaur; Raymond Lai; Charles Doillon; Hasan Uludağ
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

Review 2.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

3.  Inhibition of efflux transporter-mediated fungicide resistance in Pyrenophora tritici-repentis by a derivative of 4'-hydroxyflavone and enhancement of fungicide activity.

Authors:  Sven Reimann; Holger B Deising
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

Review 4.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD).

Authors:  Soo Kyung Cho; Ali Pedram; Ellis R Levin; Young Jik Kwon
Journal:  Biomaterials       Date:  2013-09-19       Impact factor: 12.479

6.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

7.  Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats.

Authors:  D R Kalaria; G Sharma; V Beniwal; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2008-11-08       Impact factor: 4.200

8.  Effect of valspodar on the pharmacokinetics of unbound paclitaxel.

Authors:  Albert J ten Tije; Timothy W Synold; Darcy Spicer; Jaap Verweij; James H Doroshow; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

9.  Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells.

Authors:  Zacharoula Konsoula; Mira Jung
Journal:  Biol Pharm Bull       Date:  2009-01       Impact factor: 2.233

10.  Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.

Authors:  Thomas E Hutson; Ram Ganapathi; Paul Elson; Tarek Mekhail; Thomas Olencki; G Thomas Budd; Ronald M Bukowski
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.